Skip to main content

March 2018, Vol 11, Ninth Annual Payers' Guide

FDA Approvals, Payers' Guide

Welcome to the Ninth Annual Payers’ Guide to New FDA Approvals

FDA Approvals, Introduction, Payers' Guide

FDA Approvals in 2017 Represent a 21-Year High

Gary M. Owens, MD

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2017

Payers' Guide, FDA Approvals

Aliqopa (Copanlisib), an Intravenous PI3K Inhibitor, Approved for Patients with Relapsed Follicular Lymphoma

Lisa A. Raedler, PhD, RPh

Lung Cancer, Payers' Guide, FDA Approvals, Oncology

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Besponsa (Inotuzumab Ozogamicin) Approved for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Payers' Guide, FDA Approvals

Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Dysport (AbobotulinumtoxinA) Now FDA Approved for the Treatment of Lower-Limb Spasticity in Adults

Lisa A. Raedler, PhD, RPh

Payers' Guide, FDA Approvals

Gazyva (Obinutuzumab) Approved as First-Line Treatment, with Chemotherapy, for Patients with Follicular Lymphoma

Lisa A. Raedler, PhD, RPh

Page 1 of 4
Results 1 - 10 of 31